Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendritic Cell Vaccine (Shenzhen Geno-Immune Medical Institute)
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intradermal
01
Overview
Dendritic Cell Vaccine (Shenzhen Geno-Immune Medical Institute) is a personalized autologous cell therapy designed to treat various cancers by targeting patient-specific neoantigens. The therapeutic process begins with Next-Generation Sequencing (NGS) and Whole-Exome Sequencing (WES) of the patient's tumor tissue to identify unique somatic mutations. Using proprietary HLA-restricted epitope prediction technology, the most immunogenic neoantigens are selected. These tumor-specific antigens are then loaded onto the patient's own harvested dendritic cells (DCs) ex vivo. Once matured, these engineered dendritic cells are re-infused into the patient to serve as professional antigen-presenting cells, priming and activating the immune system—specifically cytotoxic T lymphocytes—to recognize and eliminate cancer cells expressing the targeted neoepitopes.
- Other names
- Neoantigen Dendritic Cell VaccineGIMI-DC VaccineHLA-restricted Neoantigen VaccineNeoantigen-loaded Dendritic Cell Vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Dendritic Cell Vaccine (Shenzhen Geno-Immune Medical Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendritic Cell Vaccine (Shenzhen Geno-Immune Medical Institute).